Home / Health / Cancer Survivor's Hope: Experimental Vaccine Trial Success
Cancer Survivor's Hope: Experimental Vaccine Trial Success
5 Feb
Summary
- Chase Johnson, 36, received an experimental vaccine after beating aggressive breast cancer.
- The vaccine targets a protein common in 70% of triple-negative breast cancers.
- Phase 1 trials showed the vaccine to be safe, with 74% developing an immune response.
Chase Johnson, now 36, a North Carolina attorney, has remained cancer-free since undergoing treatment for aggressive triple-negative breast cancer diagnosed in February 2021. Her journey included chemotherapy, surgery, and radiation.
Facing a high risk of recurrence, Johnson sought further options and participated in a Phase 1 trial for an experimental breast cancer vaccine in December 2022. This vaccine targets a protein present in about 70% of triple-negative breast cancers.
The initial Phase 1 trials, involving 35 women like Johnson, demonstrated the vaccine's safety. Researchers observed that 74% of participants developed an immune response, with only minor side effects like localized swelling and fever.
This promising vaccine is now advancing to Phase 2 trials, which will assess its effectiveness. While still years from public availability, the developers hope it may eventually serve as both a treatment to prevent recurrence and a future prophylactic measure against breast cancer.
